Table 3.

COVID-19–specific therapies received

n (%)
Hydroxychloroquine 76 (64) 
Azithromycin 59 (50) 
Tocilizumab 15 (13) 
Lopinavir and ritonavir 12 (10) 
Convalescent plasma 11 (9) 
Favipravir 11 (9) 
Remdesivir 5 (4) 
IVIG 4 (3) 
Chloroquine 3 (3) 
Other/unknown 39 (33) 
n (%)
Hydroxychloroquine 76 (64) 
Azithromycin 59 (50) 
Tocilizumab 15 (13) 
Lopinavir and ritonavir 12 (10) 
Convalescent plasma 11 (9) 
Favipravir 11 (9) 
Remdesivir 5 (4) 
IVIG 4 (3) 
Chloroquine 3 (3) 
Other/unknown 39 (33) 
View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal